Calprotectin (Stool) at Test Zone Diagnostic Center

Calprotectin (Stool) at Test Zone Diagnostic Center

The Calprotectin (Stool) test at Test Zone Diagnostic Center is a highly specialized, non-invasive laboratory investigation used to detect and quantify gastrointestinal inflammation. Calprotectin is a 36-kilodalton calcium- and zinc-binding protein found abundantly in the cytosol of inflammatory cells, particularly neutrophils, where it constitutes up to 60% of the total cytosolic protein content. When inflammatory processes occur within the gastrointestinal tract, neutrophils migrate through the intestinal mucosal barrier into the intestinal lumen. During this migration, they degranulate and release calprotectin, which is subsequently excreted in the feces. Because calprotectin is remarkably stable in stool samples and resistant to enzymatic degradation by intestinal bacteria, it serves as an exceptionally reliable fecal biomarker for mucosal inflammation.

At Test Zone Diagnostic Center, this diagnostic test is performed using advanced laboratory technologies, such as Enzyme-Linked Immunosorbent Assay (ELISA) or chemiluminescent immunoassay (CLIA). These methodologies provide precise quantitative measurements of fecal calprotectin levels, expressed in micrograms per gram (µg/g) of stool. The primary clinical value of the Calprotectin (Stool) test lies in its high negative predictive value. A normal result strongly rules out active organic inflammatory bowel diseases, thereby sparing patients from unnecessary, invasive, and expensive diagnostic procedures such as colonoscopies or double-balloon enteroscopies. Conversely, elevated levels indicate active mucosal inflammation, guiding gastroenterologists toward appropriate diagnostic pathways, therapeutic interventions, and targeted monitoring strategies.

This test evaluates the entire length of the gastrointestinal tract, with a primary focus on the small and large intestines. It is an indispensable tool in modern gastroenterology, offering a rapid, cost-effective, and patient-friendly approach to distinguishing between functional gastrointestinal disorders, such as Irritable Bowel Syndrome (IBS), and organic inflammatory conditions, such as Inflammatory Bowel Disease (IBD), which includes Crohn's disease and Ulcerative Colitis.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your Calprotectin (Stool) test results at Test Zone Diagnostic Center, careful patient preparation is essential. Certain medications and clinical factors can artificially alter fecal calprotectin levels, potentially leading to false-positive or false-negative results. Please adhere strictly to the following preparation guidelines:

• Medication Review: Inform your prescribing physician and the laboratory staff of all medications, supplements, and over-the-counter drugs you are currently taking.
• Avoid NSAIDs: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, naproxen, diclofenac, and high-dose aspirin, can cause mild, subclinical inflammation of the intestinal mucosa. It is highly recommended to discontinue these medications for at least two weeks prior to sample collection, under the direct supervision of your healthcare provider.
• Proton Pump Inhibitors (PPIs): Long-term use of PPIs (e.g., omeprazole, esomeprazole, lansoprazole) can alter the gut microbiome and cause mild intestinal mucosal irritation, leading to borderline elevated calprotectin levels. If clinically feasible, discuss the temporary suspension of these medications with your physician.
• No Dietary Restrictions: There are no specific dietary restrictions required for this test. You may eat and drink normally prior to sample collection.
• Avoid Contamination: Do not collect stool samples during periods of active hemorrhoidal bleeding, menstrual bleeding, or severe urinary tract infections, as blood or urine contamination can compromise the sample.
• Sterile Collection Container: Use only the sterile, preservative-free stool collection container provided by Test Zone Diagnostic Center. Do not use any other household containers.

During the Procedure

The collection of a stool sample for the Calprotectin (Stool) test is a simple, painless, and completely safe procedure that is typically performed by the patient in the comfort of their home. Understanding the correct collection protocol is vital for maintaining sample integrity:

• Sanitation: Wash your hands thoroughly with soap and warm water before beginning the collection process.
• Sample Collection: Pass stool into a clean, dry receptacle or onto a clean sheet of plastic wrap stretched across the toilet bowl. It is critical that the stool sample does not come into contact with toilet water, urine, or household cleaning chemicals, as these substances can degrade the calprotectin protein.
• Transferring the Specimen: Use the sterile spoon or spatula attached to the cap of the collection container provided by Test Zone Diagnostic Center to scoop a small portion of the stool. A sample size equivalent to the size of a walnut (approximately 1 to 2 grams for solid stool, or 1 to 2 milliliters for liquid stool) is sufficient for analysis.
• Securing the Container: Place the sample into the sterile container and screw the cap on tightly to prevent leakage. Ensure the exterior of the container remains clean and uncontaminated.
• Labeling: Clearly write your full name, date of birth, and the exact date and time of collection on the container label.
• Prompt Delivery: Deliver the specimen to Test Zone Diagnostic Center as soon as possible, ideally within 2 to 4 hours of collection. If a delay is unavoidable, store the sample in a refrigerator at 2°C to 8°C. Do not freeze the sample, and do not leave it exposed to direct sunlight or high temperatures.

When is a Calprotectin (Stool) Performed?

Differentiating IBD from IBS

Physicians frequently request a Calprotectin (Stool) test when a patient presents with chronic gastrointestinal symptoms that could indicate either Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD). IBS is a functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits without any structural, biochemical, or inflammatory abnormalities. In contrast, IBD involves chronic, progressive, and potentially destructive mucosal inflammation. Because the clinical presentations of these two conditions overlap significantly, fecal calprotectin serves as an invaluable, non-invasive triage tool. A low or normal calprotectin level strongly supports a diagnosis of IBS, reducing the need for invasive diagnostic procedures, while an elevated level points toward IBD, prompting immediate endoscopic evaluation.

Monitoring Inflammatory Bowel Disease (IBD) Activity

For patients with a confirmed diagnosis of Crohn's disease or Ulcerative Colitis, the Calprotectin (Stool) test is performed periodically to monitor disease activity. Clinical symptoms alone are often unreliable indicators of mucosal inflammation, as patients can experience clinical remission while significant subclinical inflammation persists. Regular measurement of fecal calprotectin levels allows gastroenterologists to objectively assess the inflammatory status of the gut. This proactive monitoring helps in predicting clinical relapses or flare-ups weeks before symptoms manifest, allowing for timely adjustments in medication dosages and preventing disease progression or complications.

Investigating Chronic Diarrhea and Abdominal Pain

Chronic diarrhea (lasting more than four weeks) accompanied by persistent abdominal pain, cramping, unexplained weight loss, or low-grade fever warrants comprehensive diagnostic investigation. A Calprotectin (Stool) test is performed in these clinical scenarios to determine whether the symptoms are driven by an underlying inflammatory process. By identifying the presence of mucosal inflammation, the test helps clinicians narrow down the differential diagnosis, ruling out non-inflammatory causes of chronic diarrhea such as osmotic diarrhea, malabsorption syndromes, or functional disorders, and focusing on inflammatory etiologies.

Assessing Response to Gastrointestinal Therapy

When a patient begins a new therapeutic regimen for IBD—such as corticosteroids, immunomodulators, biologics (e.g., anti-TNF agents), or targeted small molecules—physicians must evaluate the efficacy of the treatment. The Calprotectin (Stool) test is performed at baseline and at specific intervals during therapy to track the reduction of mucosal inflammation. A significant decline in fecal calprotectin levels indicates a positive response to treatment, confirming that the therapeutic intervention is successfully dampening the inflammatory cascade and promoting mucosal healing.

Screening for Intestinal Mucosal Healing

In modern IBD management, the ultimate therapeutic goal has shifted from merely controlling clinical symptoms to achieving complete mucosal healing. Mucosal healing is associated with long-term clinical remission, reduced hospitalization rates, and a lower requirement for surgical bowel resections. Because repeated colonoscopies to visualize the mucosa are impractical, invasive, and carry risks, the Calprotectin (Stool) test is performed as a surrogate marker. Normalization of fecal calprotectin levels correlates strongly with endoscopic and histological mucosal healing, providing a reliable, non-invasive method to confirm deep tissue recovery.

What Does a Calprotectin (Stool) Detect?

The Calprotectin (Stool) test is highly sensitive to neutrophilic inflammation within the gastrointestinal tract. Depending on the clinical context and the quantitative value obtained, the test can detect, monitor, or suggest several conditions and physiological states, including:

• Active Ulcerative Colitis: Characterized by diffuse mucosal inflammation starting in the rectum and extending proximally into the colon, resulting in highly elevated calprotectin levels.
• Active Crohn's Disease: Marked by patchy, transmural inflammation that can affect any part of the gastrointestinal tract from the mouth to the anus, leading to significant calprotectin elevation.
• Infectious Colitis: Acute bacterial infections of the colon (e.g., caused by Salmonella, Shigella, Campylobacter, or Clostridioides difficile) trigger a robust neutrophilic response, causing elevated calprotectin.
• NSAID-Induced Enteropathy: Chronic use of non-steroidal anti-inflammatory drugs can cause small bowel mucosal erosions and inflammation, detected as mild to moderate calprotectin elevations.
• Microscopic Colitis: Including lymphocytic and collagenous colitis, which involve chronic watery diarrhea and mild mucosal inflammation.
• Diverticulitis: Acute inflammation of diverticula in the colon wall leads to localized neutrophilic infiltration and elevated fecal calprotectin.
• Celiac Disease: Active, untreated celiac disease with significant small intestinal mucosal inflammation can cause mild to moderate elevations.
• Gastrointestinal Malignancies: Colorectal cancer or gastric cancer can cause localized mucosal inflammation, ulceration, and bleeding, resulting in elevated calprotectin levels.
• Large Inflammatory Polyps: Benign but highly inflamed or ulcerated polyps in the colon can shed neutrophils, raising calprotectin concentrations.
• Food Protein-Induced Enterocolitis Syndrome (FPIES): An allergic gastrointestinal reaction, primarily in pediatric patients, that can cause mucosal inflammation.
• Necrotizing Enterocolitis (NEC): A serious gastrointestinal disease in premature infants characterized by intestinal inflammation and necrosis, marked by elevated calprotectin.
• Peptic Ulcer Disease: Severe, active gastric or duodenal ulcers with associated inflammatory responses can cause mild elevations.
• Parasitic Gastrointestinal Infections: Infections such as amebiasis or giardiasis that cause mucosal irritation and inflammatory cell recruitment.
• Radiation Proctitis or Enteritis: Mucosal inflammation of the bowel resulting from pelvic or abdominal radiation therapy.
• Ischemic Colitis: Reduced blood flow to the colon leading to mucosal injury, inflammation, and elevated calprotectin levels.
• Autoimmune Enteropathy: A rare disorder characterized by intractable diarrhea and autoimmune-mediated intestinal mucosal inflammation.
• Eosinophilic Gastroenteritis: An uncommon inflammatory disease characterized by eosinophilic infiltration of gastrointestinal tissues, which can sometimes elevate calprotectin.
• Systemic Vasculitis: Conditions such as IgA vasculitis (Henoch-Schönlein purpura) that involve the gastrointestinal tract and cause mucosal inflammation.
• Successful Mucosal Healing: A normal calprotectin level in a known IBD patient indicates the resolution of mucosal inflammation and successful therapeutic response.
• Subclinical Relapse: A rising trend in calprotectin levels in an asymptomatic IBD patient, indicating early, silent mucosal inflammation before clinical symptoms reappear.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely diagnostic results are crucial for effective clinical decision-making and patient peace of mind. The Calprotectin (Stool) test is processed using state-of-the-art automated immunoassay platforms, ensuring both high accuracy and rapid turnaround times. Typically, the verified test report is available within 24 to 48 hours after the laboratory receives the stool specimen.

Patients and referring physicians can access reports conveniently through multiple digital channels. Once the clinical pathologists verify the findings, an automated SMS notification containing a secure download link is sent to the patient's registered mobile number. Reports can also be accessed, viewed, and downloaded directly from the official Test Zone Diagnostic Center online portal. For patients who prefer physical copies, printed reports can be collected from the main diagnostic center or any of our official collection points.

Calprotectin (Stool) Findings Overview

The following table provides a general clinical guide to the interpretation of fecal calprotectin levels. Results must always be correlated with the patient's specific clinical history and symptoms.

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Fecal Calprotectin Concentration	< 50 µg/g (Indicates no significant gastrointestinal inflammation)	≥ 50 µg/g to 120 µg/g (Borderline/Mild elevation); > 120 µg/g (Significant elevation)
Intestinal Mucosa Integrity	Intact mucosal barrier; no active neutrophilic migration into the intestinal lumen	Compromised mucosal barrier; active inflammation, ulceration, or mucosal erosions
Inflammatory Bowel Disease (IBD) Activity	Clinical and mucosal remission in known IBD patients	Active disease flare-up, subclinical inflammation, or impending clinical relapse
Irritable Bowel Syndrome (IBS) Differentiation	Supports functional bowel disorder (IBS); rules out organic inflammatory pathology	Suggests organic pathology (IBD, infection, or enteropathy); rules out simple IBS
Gastrointestinal Infection Status	No active bacterial or parasitic infection causing mucosal inflammation	Active infectious colitis (bacterial, parasitic, or pseudomembranous colitis)
Response to Anti-inflammatory Therapy	Normalization of calprotectin levels, confirming successful therapeutic response	Persistently high or rising calprotectin levels, indicating treatment failure or non-adherence
Drug-Induced Mucosal Irritation	No significant mucosal damage from medications	Mild to moderate mucosal inflammation secondary to chronic NSAID or PPI use

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Calprotectin (Stool)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified clinical pathologists, technologists, and laboratory technicians dedicated to maintaining the highest standards of diagnostic accuracy.
• Patient-Focused Care: We prioritize patient comfort, safety, and convenience, providing clear instructions and support throughout the sample collection and testing process.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to stringent internal and external quality control protocols to ensure reliable, reproducible, and clinically precise test results.
• Professional Reporting: Our diagnostic reports are comprehensive, easy to understand, and structured to provide referring physicians with clear, actionable clinical insights.
• Modern Diagnostic Approach: We utilize advanced, fully automated immunoassay platforms and state-of-the-art laboratory equipment to perform fecal calprotectin assays.
• Comfortable Environment: Our diagnostic facilities are designed to offer a clean, hygienic, and welcoming environment for all patients and visitors.
• Convenient Location: Strategically located with easily accessible sample collection points, making it simple for patients to drop off specimens.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely, evidence-based diagnostic services that support early detection, effective treatment, and improved patient outcomes.